Sign inJoin waitlistJoin the waitlist

Eric Jacobsen

Director, Center for Adult Histiocyte Disorders · Mass General Brigham

Credentials: · · · ·

History

Center for Adult Histiocyte Disorders · Mass General Brigham
Present
Adult Lymphoma Program · Mass General Brigham
Present
Histiocyte Disorders Center · Mass General Brigham
Present

Dana-Farber Cancer Institute
2002–2004
Internal Medicine
Johns Hopkins Hospital
1999–2002
University of Connecticut School of Medicine
1995–1999

Research

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · 4,914 citations
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte…
Journal of Clinical Oncology · 2009 · 564 citations
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
Journal of Clinical Oncology · 2011 · 539 citations

David Fisher
48 papers
Ann LaCasce
41 papers
Philippe Armand
40 papers
Arnold Freedman
29 papers
Caron Jacobsen
29 papers
Jennifer Brown
28 papers
Matthew Davids
22 papers
SH
Steven Horwitz
20 papers
Austin Kim
18 papers
JB
Jeffrey Barnes
18 papers
Reid Merryman
16 papers · 4 as a fellow
Jennifer Crombie
15 papers · 1 as a fellow

Clinical trials

Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Principal investigator · Withdrawn · Phase 2
Eric Jacobsen, MD
2024–2032
Pembrolizumab in Neoplasms or Lymphomas
Principal investigator · Suspended · Phase 2
Dana-Farber Cancer Institute
2017–2026
Lenalidomide for Adult Histiocyte Disorders
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2015–2026
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2008–2013